Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Caribou Biosciences Shared Its First Clinical Data From Dose Escalation In The Ongoing CaMMouflage Phase 1 Trial Of CB-011, An Off-The-Shelf Anti-BCMA CAR-T Cell Therapy, In Relapsed Or Refractory Multiple Myeloma; The Company Plans To Share Dose Expansion Data In 2026

Author: Benzinga Newsdesk | November 03, 2025 07:14am
  • First clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.
  • 450 million cell dose is the recommended dose for expansion (RDE); dose expansion to initiate by year end and data expected in 2026.
  • 92% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve cohort treated at the RDE with the selected lymphodepletion regimen

Posted In: CRBU


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist